Skip to main content
SpringerLink
Log in

Key molecular mechanisms associated with cell malignant transformation in acute myeloid leukemia

  • Reviews
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

Cancer, along with cardiovascular disorders, is one of the most important problems of healthcare. Pathologies of the hematopoietic system are the most prevalent in patients under 30 years of age, including acute myeloid leukemia (AML), which is widespread and difficult to treat. The review considers the mechanisms that play a significant role in AML cell malignant transformation and shows the contributions of certain genes to both remission and resistance of AML cells to various treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AML:

acute myeloid leukemia

Bcl-2:

B-cell lymphoma 2

Bcl-xL:

B-cell lymphoma-extra large

FLT-3:

fmsrelated tyrosine kinase 3

Mcl-2:

myeloid leukemia cell differentiation protein 2

XP:

xeroderma pigmentosum

XPA–F:

XP complementation groups A–F

ERCC1:

excision repair crosscomplementing group 1

Hh:

hedgehog genes

Ptc:

Patched

Gli1–3:

hlioma-associated oncogene homologs 1–3

JNK:

c-Jun N-terminal kinase

MAPK:

mitogen-activated protein kinase

Bcr-Abl:

breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1

BER:

base excision repair

NER:

nucleotide excision repair

MMR:

mismatch repair

References

  1. McIlwain D.R., Berger T., Mak T.W. 2013. Caspase functions in cell death and disease. Cold Spring Harbor Persp. Biol. 5 (4), a008656.

    Google Scholar 

  2. Logue S.E., Martin S.J. 2008. Mammalian caspase activation pathways in apoptosis and inflamation. In: Design of Caspase Inhibitors as Potential Clinical Agents. Eds O’Brien T., Linton S.D. Boca Raton, FL: CRC Press, pp. 1–13.

    Chapter  Google Scholar 

  3. Dorn D.C., Kou C.A., Png K.J., Moore M.A. 2009. The effect of cantharidins on leukemic stem cells. Int. J. Cancer. 124 (9), 2186–2199.

    Article  CAS  PubMed  Google Scholar 

  4. Friesen C., Roscher M., Hormann I., Leib O., Marx S., Moreno J., Miltner E. 2013. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio-and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur. J. Cancer. 49 (11), 2542–2554.

    Article  CAS  PubMed  Google Scholar 

  5. Hassan H.T. 2004. Ajoene (natural garlic compound): A new anti-leukaemia agent for AML therapy. Leukemia Res. 28 (7), 667–671.

    Article  CAS  Google Scholar 

  6. Bogenberger J., Kornblau S., Pierceall W., Lena R., Chow D., Shi C., Mantei J., Ahmann G., Gonzales I., Choudhary A. 2014. BCL-2 family proteins as 5-azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 28 (8), 1657–1665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ragusa M., Avola G., Angelica R., Barbagallo D., Guglielmino M.R., Duro L.R., Majorana A., Statello L., Salito L., Consoli C. 2010). Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer. 10 (1), 377.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wang M., Wang L., Cui J., Zhou H. 2013. Expression and clinical significance of B-cell lymphoma 2 (BCL-2) in hyperleukocytic acute myeloid leukemia. J. Exp. Hematol./Chinese Assoc. Pathophysiol. 21 (4), 851–856.

    CAS  Google Scholar 

  9. Beurlet S., Omidvar N., Gorombei P., Krief P., Le Pogam C., Setterblad N., de la Grange P., Leboeuf C., Janin A., Noguera M.-E. 2013. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 122 (16), 2864–2876.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mehta S., Shukla S., Vora H. 2012. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: Its correlation with FLT3. Neoplasma. 60 (6), 666–675.

    Article  Google Scholar 

  11. Sahu G., Jena R.K. 2011. Clinical significance of P53 and Bcl-2 in acute myeloid leukemia patients of Eastern India. Hematol. Repts. 3 (3), e28.

    Google Scholar 

  12. Poeta G., Bruno A., Del Principe M., Venditti A., Maurillo L., Buccisano F., Stasi R., Neri B., Luciano F., Siniscalchi A. 2008. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr. Cancer Drug Targets. 8 (3), 207–222.

    Article  PubMed  Google Scholar 

  13. Bose P., Grant S. 2013. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leukemia Res. Repts. 2 (1), 12–14.

    Article  Google Scholar 

  14. Katragadda L., Carter B.Z., Borthakur G. 2013. XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin. Invest. Drugs. 22 (5), 663–670.

    Article  CAS  Google Scholar 

  15. Pluta A., Wrzesien-Kus A., Cebula-Obrzut B., Wolska A., Szmigielska-Kaplon A., Czemerska M., Pluta P., Robak T., Smolewski P., Wierzbowska A. 2010. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leukemia Res. 34 (10), 1308–1313.

    Article  CAS  Google Scholar 

  16. Estrov Z., Thall P.F., Talpaz M., Estey E.H., Kantarjian H.M., Andreeff M., Harris D., Van Q., Walterscheid M., Kornblau S.M. 1998. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood. 92 (9), 3090–3097.

    CAS  PubMed  Google Scholar 

  17. Allan J.M., Smith A.G., Wheatley K., Hills R.K., Travis L.B., Hill D.A., Swirsky D.M., Morgan G.J., Wild C.P. 2004. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood. 104 (13), 3872–3877.

    Article  CAS  PubMed  Google Scholar 

  18. Kuptsova-Clarkson N., Ambrosone C.B., Weiss J., Baer M.R., Sucheston L.E., Zirpoli G., Kopecky K.J., Ford L., Blanco J., Wetzler M. 2010. XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia. Int. J. Mol. Epidemiol. Genet. 1 (4), 278.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Diamond H.R., Ornellas M.H., Orfao A., Gomes B.E., Campos M.M., Fernandez T.S., da Silva R.I., Alves G., Lage C., da Silva D.A. 2011. Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. J. Hematol. Oncol. 4, 39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Economopoulou P., Pappa V., Kontsioti F., Papageorgiou S., Foukas P., Liakata E., Economopoulou C., Vassilatou D., Ioannidou E.-D., Chondropoulos S. 2010. Expression analysis of proteins involved in the non homologous end joining DNA repair mechanism, in the bone marrow of adult de novo myelodysplastic syndromes. Ann. Hematol. 89 (3), 233–239.

    Article  CAS  PubMed  Google Scholar 

  21. Kobune M., Takimoto R., Murase K., Iyama S., Sato T., Kikuchi S., Kawano Y., Miyanishi K., Sato Y., Niitsu Y. 2009. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci. 100 (5), 948–955.

    Article  CAS  PubMed  Google Scholar 

  22. Pan D., Li Y., Li Z., Wang Y., Wang P., Liang Y. 2012. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leukemia Res. 36 (6), 742–748.

    Article  CAS  Google Scholar 

  23. Boyd A.L., Salci K.R., Shapovalova Z., McIntyre B.A., Bhatia M. 2013. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors. Exp. Hematol. 41 (10), 858–869.

    Article  CAS  PubMed  Google Scholar 

  24. Gupta S., Campbell D., Derijard B., Davis R.J. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science. 267 (5196), 389–393.

    Article  CAS  PubMed  Google Scholar 

  25. Davis R.J. 2000. Signal transduction by the JNK group of MAP kinases. Cell. 103 (2), 239–252.

    Article  CAS  PubMed  Google Scholar 

  26. Bubici C., Papa S. 2014. JNK signalling in cancer: In need of new, smarter therapeutic targets. Br. J. Pharmacol. 171 (1), 24–37.

    Article  CAS  PubMed  Google Scholar 

  27. Manning A.M., Davis R.J. 2003. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2 (7), 554–565.

    Article  CAS  Google Scholar 

  28. Chang Q., Chen J., Beezhold K.J., Castranova V., Shi X., Chen F. 2009. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol. Cancer. 8, 64.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hui L., Zatloukal K., Scheuch H., Stepniak E., Wagner E.F. 2008. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J. Clin. Invest. 118 (12), 3943–3953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Cripe L.D., Gelfanov V.M., Smith E.A., Spigel D.R., Phillips C.A., Gabig T.G., Jung S.H., Fyffe J., Hartman A.D., Kneebone P., Mercola D., Burgess G.S., Boswell H.S. 2002. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): Signaling to multidrug-efflux and hyperproliferation. Leukemia. 16 (5), 799–812.

    Article  CAS  PubMed  Google Scholar 

  31. Yan F., Wang X.M., Liu Z.C., Pan C., Yuan S.B., Ma Q.M. 2010. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatob. Pancreat. Dis. Int. 9 (3), 287–295.

    CAS  Google Scholar 

  32. Cui J., Zhang M., Zhang Y.Q., Xu Z.H. 2007. JNK pathway: diseases and therapeutic potential. Acta Pharmacol. Sin. 28 (5), 601–608.

    Article  CAS  PubMed  Google Scholar 

  33. Wagner E.F., Nebreda A.R. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer. 9 (8), 537–549.

    Article  CAS  PubMed  Google Scholar 

  34. Oleinik N.V., Krupenko N.I., Krupenko S.A. 2007. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene. 26 (51), 7222–7230.

    Article  CAS  PubMed  Google Scholar 

  35. Yang D.D., Conze D., Whitmarsh A.J., Barrett T., Davis R.J., Rincon M., Flavell R.A. 1998. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity. 9 (4), 575–585.

    Article  CAS  PubMed  Google Scholar 

  36. Heasley L.E., Han S.Y. 2006. JNK regulation of oncogenesis. Mol. Cells. 21 (2), 167–173.

    CAS  PubMed  Google Scholar 

  37. Bullinger L., Rucker F.G., Kurz S., Du J., Scholl C., Sander S., Corbacioglu A., Lottaz C., Krauter J., Frohling S., Ganser A., Schlenk R.F., Dohner K., Pollack J.R., Dohner H. 2007. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood. 110 (4), 1291–1300.

    Article  CAS  PubMed  Google Scholar 

  38. Yamamoto K., Ichijo H., Korsmeyer S.J. 1999. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol. Cell. Biol. 19 (12), 8469–8478.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kharbanda S., Saxena S., Yoshida K., Pandey P., Kaneki M., Wang Q., Cheng K., Chen Y.N., Campbell A., Sudha T., Yuan Z.M., Narula J., Weichselbaum R., Nalin C., Kufe D. 2000. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J. Biol. Chem. 275 (1), 322–327.

    Article  CAS  PubMed  Google Scholar 

  40. Mehta S.V., Shukla S.N., Vora H.H. 2013. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma. 60 (6), 666–675.

    Article  CAS  PubMed  Google Scholar 

  41. Belov A.A., Mohammadi M. 2012. Grb2, a doubleedged sword of receptor tyrosine kinase signaling. Sci. Signal. 5 (249), pe49.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Wang L., Yang L., Burns K., Kuan C.Y., Zheng Y. 2005. Cdc42GAP regulates c-Jun N-terminal kinase (JNK)- mediated apoptosis and cell number during mammalian perinatal growth. Proc. Natl. Acad. Sci. U. S. A. 102 (38), 13484–13489.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Habelhah H., Takahashi S., Cho S.G., Kadoya T., Watanabe T., Ronai Z. 2004. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J. 23 (2), 322–332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Yagi T., Morimoto A., Eguchi M., Hibi S., Sako M., Ishii E., Mizutani S., Imashuku S., Ohki M., Ichikawa H. 2003. Identification of a gene expression signature associated with pediatric AML prognosis. Blood. 102 (5), 1849–1856.

    Article  CAS  PubMed  Google Scholar 

  45. Zarubin T., Han J. 2005. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15 (1), 11–18.

    Article  CAS  PubMed  Google Scholar 

  46. Cuenda A., Rousseau S. 2007. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta. 1773 (8), 1358–1375.

    Article  CAS  PubMed  Google Scholar 

  47. Koul H.K., Pal M., Koul S. 2013. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 4 (9–10), 342–359.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Greenberg A.K., Basu S., Hu J., Yie T.A., Tchou-Wong K.M., Rom W.N., Lee T.C. 2002. Selective p38 activation in human non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 26 (5), 558–564.

    Article  CAS  PubMed  Google Scholar 

  49. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., Arteaga C.L., Moses H.L. 2001. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell. 12 (1), 27–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Comes F., Matrone A., Lastella P., Nico B., Susca F.C., Bagnulo R., Ingravallo G., Modica S., Lo Sasso G., Moschetta A., Guanti G., Simone C. 2007. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ. 14 (4), 693–702.

    Article  CAS  PubMed  Google Scholar 

  51. Verma A., Mohindru M., Deb D.K., Sassano A., Kambhampati S., Ravandi F., Minucci S., Kalvakolanu D.V., Platanias L.C. 2002. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J. Biol. Chem. 277 (47), 44988–44995.

    Article  CAS  PubMed  Google Scholar 

  52. Loesch M., Chen G. 2008). The p38 MAPK stress pathway as a tumor suppressor or more? Front Biosci. 13, 3581–3593.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Dumka D., Puri P., Carayol N., Lumby C., Balachandran H., Schuster K., Verma A.K., Terada L.S., Platanias L.C., Parmar S. 2009. Activation of the p38 MAP kinase pathway is essential for the antileukemic effects of dasatinib. Leuk. Lymphoma. 50 (12), 2017–2029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Maia V., Sanz M., Gutierrez-Berzal J., de Luis A., Gutierrez-Uzquiza A., Porras A., Guerrero C. 2009. C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival. Cell Signal. 21 (7), 1229–1235.

    Article  CAS  PubMed  Google Scholar 

  55. Bragado P., Armesilla A., Silva A., Porras A. 2007. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 12 (9), 1733–1742.

    Article  CAS  PubMed  Google Scholar 

  56. Vergarajauregui S., San Miguel A., Puertollano R. 2006. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. Traffic. 7 (6), 686–698.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Nobes C.D., Hall A. 1995. Rho, rac and cdc42 GTPases: Regulators of actin structures, cell adhesion and motility. Biochem. Soc. Trans. 23 (3), 456–459.

    Article  CAS  PubMed  Google Scholar 

  58. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. 1997. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275 (5296), 90–94.

    Article  CAS  PubMed  Google Scholar 

  59. Cuadrado A., Nebreda A.R. 2010. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 429 (3), 403–417.

    Article  CAS  PubMed  Google Scholar 

  60. Schulte G., Fredholm B.B. 2003. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal. 15 (9), 813–827.

    Article  CAS  PubMed  Google Scholar 

  61. Radmacher M.D., Marcucci G., Ruppert A.S., Mrozek K., Whitman S.P., Vardiman J.W., Paschka P., Vukosavljevic T., Baldus C.D., Kolitz J.E., Caligiuri M.A., Larson R.A., Bloomfield C.D. 2006. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: A Cancer and Leukemia Group B study. Blood. 108 (5), 1677–1683.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Piek E., Heldin C.H., Ten Dijke P. 1999. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 13 (15), 2105–2124.

    CAS  PubMed  Google Scholar 

  63. Glick A.B., Weinberg W.C., Wu I.H., Quan W., Yuspa S.H. 1996. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res. 56 (16), 3645–3650.

    CAS  PubMed  Google Scholar 

  64. Kim S.J., Letterio J. 2003. Transforming growth factorbeta signaling in normal and malignant hematopoiesis. Leukemia. 17 (9), 1731–1737.

    Article  CAS  PubMed  Google Scholar 

  65. Massague J. 2008. TGFbeta in cancer. Cell. 134 (2), 215–230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Katz L.H., Li Y., Chen J.S., Munoz N.M., Majumdar A., Chen J., Mishra L. 2013. Targeting TGF-beta signaling in cancer. Expert Opin. Ther. Targets. 17 (7), 743–760.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Meulmeester E., Ten Dijke P. 2011. The dynamic roles of TGF-beta in cancer. J. Pathol. 223 (2), 205–218.

    Article  CAS  PubMed  Google Scholar 

  68. Childs C.B., Proper J.A., Tucker R.F., Moses H.L. 1982. Serum contains a platelet-derived transforming growth factor. Proc. Natl. Acad. Sci. U. S. A. 79 (17), 5312–5316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Rifkin D.B. 2005. Latent transforming growth factorbeta (TGF-beta) binding proteins: Orchestrators of TGF-beta availability. J. Biol. Chem. 280 (9), 7409–7412.

    Article  CAS  PubMed  Google Scholar 

  70. Derynck R., Zhang Y.E. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425 (6958), 577–584.

    Article  CAS  PubMed  Google Scholar 

  71. Fortunel N.O., Hatzfeld A., Hatzfeld J.A. 2000. Transforming growth factor-beta: Pleiotropic role in the regulation of hematopoiesis. Blood. 96 (6), 2022–2036.

    CAS  PubMed  Google Scholar 

  72. Jacobsen S.E., Ruscetti F.W., Dubois C.M., Lee J., Boone T.C., Keller J.R. 1991. Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. Blood. 77 (8), 1706–1716.

    CAS  PubMed  Google Scholar 

  73. Heinrich M.C., Dooley D.C., Keeble W.W. 1995. Transforming growth factor beta 1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood. 85 (7), 1769–1780.

    CAS  PubMed  Google Scholar 

  74. Kelly L.M., Gilliland D.G. 2002. Genetics of myeloid leukemias. Annu. Rev. Genomics Hum. Genet. 3, 179–198.

    Article  CAS  PubMed  Google Scholar 

  75. Malaise M., Steinbach D., Corbacioglu S. 2009. Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr. Hematol. Malig. Rep. 4 (2), 77–82.

    Article  PubMed  Google Scholar 

  76. Roberts A.B., Derynck R. 2001. Meeting report: Signaling schemes for TGF-beta. Science’s STKE. 2001 (113), pe43.

    CAS  PubMed  Google Scholar 

  77. Wilson C.S., Davidson G.S., Martin S.B., Andries E., Potter J., Harvey R., Ar K., Xu Y., Kopecky K.J., Ankerst D.P., Gundacker H., Slovak M.L., Mosquera-Caro M., Chen I.M., Stirewalt D.L., et al. 2006. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 108 (2), 685–696.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Lu T., Tian L., Han Y., Vogelbaum M., Stark G.R. 2007. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 104 (11), 4365–4370.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Burgess G.S., Williamson E.A., Cripe L.D., Litz-Jackson S., Bhatt J.A., Stanley K., Stewart M.J., Kraft A.S., Nakshatri H., Boswell H.S. 1998. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 92 (7), 2450–2460.

    CAS  PubMed  Google Scholar 

  80. Rangatia J., Vangala R.K., Singh S.M., Peer Zada A.A., Elsasser A., Kohlmann A., Haferlach T., Tenen D.G., Hiddemann W., Behre G. 2003. Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction. Oncogene. 22 (30), 4760–4764.

    Article  CAS  PubMed  Google Scholar 

  81. Zada A.A., Singh S.M., Reddy V.A., Elsasser A., Meisel A., Haferlach T., Tenen D.G., Hiddemann W., Behre G. 2003. Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene. 22 (15), 2296–2308.

    Article  CAS  PubMed  Google Scholar 

  82. Okutsu J., Tsunoda T., Kaneta Y., Katagiri T., Kitahara O., Zembutsu H., Yanagawa R., Miyawaki S., Kuriyama K., Kubota N., Kimura Y., Kubo K., Yagasaki F., Higa T., Taguchi H., et al. 2002. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol. Cancer Ther. 1 (12), 1035–1042.

    CAS  PubMed  Google Scholar 

  83. Li Y., Liang M., Zhang Z. 2014. Regression analysis of combined gene expression regulation in acute myeloid leukemia. PLoS Comput. Biol. 10 (10), e1003908.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Staber P.B., Linkesch W., Zauner D., Beham-Schmid C., Guelly C., Schauer S., Sill H., Hoefler G. 2004. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene. 23 (4), 894–904.

    Article  CAS  PubMed  Google Scholar 

  85. Levy L., Hill C.S. 2006. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17 (1–2), 41–58.

    Article  CAS  PubMed  Google Scholar 

  86. Akiyama Y., Iwanaga R., Saitoh K., Shiba K., Ushio K., Ikeda E., Iwama T., Nomizu T., Yuasa Y. 1997. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology. 112 (1), 33–39.

    Article  CAS  PubMed  Google Scholar 

  87. Dong M., Blobe G.C. 2006. Role of transforming growth factor-beta in hematologic malignancies. Blood. 107 (12), 4589–4596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia

    N. N. Orlova, T. D. Lebedev, P. V. Spirin & V. S. Prassolov

Authors
  1. N. N. Orlova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. D. Lebedev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. V. Spirin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. S. Prassolov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. S. Prassolov.

Additional information

Original Russian Text © N.N. Orlova, T.D. Lebedev, P.V. Spirin, V.S. Prassolov, 2016, published in Molekulyarnaya Biologiya, 2016, Vol. 50, No. 3, pp. 395–405.

These authors equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orlova, N.N., Lebedev, T.D., Spirin, P.V. et al. Key molecular mechanisms associated with cell malignant transformation in acute myeloid leukemia. Mol Biol 50, 344–352 (2016). https://doi.org/10.1134/S0026893316020187

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893316020187

Keywords

Search

Navigation